Seres Therapeutics, Inc. (MCRB) EPS Estimated At $-0.74; Shire plc (SHPG) Covered By 22 Bulls

April 17, 2018 - By Peter Erickson

Shire plc (NASDAQ:SHPG) Logo

Among 27 analysts covering Shire plc (ADR) (NASDAQ:SHPG), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 81% are positive. Shire plc (ADR) had 76 analyst reports since July 22, 2015 according to SRatingsIntel. FBR Capital initiated the shares of SHPG in report on Wednesday, October 18 with “Buy” rating. The firm has “Buy” rating given on Tuesday, January 2 by Stifel Nicolaus. As per Monday, September 28, the company rating was maintained by RBC Capital Markets. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, August 15. On Tuesday, July 25 the stock rating was maintained by Piper Jaffray with “Hold”. The rating was upgraded by Bank of America on Friday, January 15 to “Buy”. The company was initiated on Monday, May 23 by Bryan Garnier & Cie. The firm has “Hold” rating by HSBC given on Wednesday, September 30. RBC Capital Markets maintained it with “Buy” rating and $21800 target in Wednesday, June 7 report. The firm has “Buy” rating given on Tuesday, September 5 by Jefferies. See Shire plc (NASDAQ:SHPG) latest ratings:

28/03/2018 Broker: Bank of America Rating: Buy Maintain
21/03/2018 Broker: Oppenheimer Rating: Buy
22/02/2018 Broker: Bank of America Rating: Buy Maintain
23/02/2018 Broker: FBR Capital Rating: Buy Maintain
19/02/2018 Broker: J.P. Morgan Rating: Hold New Target: $150.0 Downgrade
20/02/2018 Broker: each representing three Ordinary Shares Rating: Jp Morgan
16/02/2018 Broker: Susquehanna Rating: Buy New Target: $200.0 Maintain
14/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $150.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $181.0 Maintain
15/02/2018 Broker: Jefferies Rating: Buy New Target: $172.0 Maintain

Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.74 EPS on May, 3.They anticipate $0.11 EPS change or 17.46% from last quarter’s $-0.63 EPS. After having $-0.71 EPS previously, Seres Therapeutics, Inc.’s analysts see 4.23% EPS growth. The stock increased 1.04% or $0.08 during the last trading session, reaching $7.75. About 15,424 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 31.05% since April 17, 2017 and is downtrending. It has underperformed by 42.60% the S&P500.

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 25 analyst reports since July 21, 2015 according to SRatingsIntel. Leerink Swann initiated it with “Outperform” rating and $60 target in Tuesday, July 21 report. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. Cantor Fitzgerald maintained the stock with “Buy” rating in Thursday, October 19 report. The company was initiated on Wednesday, March 30 by FBR Capital. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Neutral” rating given on Tuesday, July 21 by Goldman Sachs. The firm has “Buy” rating by Bank of America given on Thursday, October 22. FBR Capital maintained the stock with “Outperform” rating in Wednesday, February 1 report. The stock has “Neutral” rating by Bank of America on Tuesday, July 21. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Buy” rating given on Wednesday, July 22 by Canaccord Genuity. The rating was maintained by Oppenheimer on Tuesday, March 20 with “Buy”.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $315.03 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

The stock increased 1.90% or $2.89 during the last trading session, reaching $155.3. About 378,003 shares traded. Shire plc (NASDAQ:SHPG) has declined 27.67% since April 17, 2017 and is downtrending. It has underperformed by 39.22% the S&P500.

Shire plc (NASDAQ:SHPG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts